Eortc Bladder Cancer Calculator - NMIBC Recurrence and Progression

The EORTC bladder cancer calculator is a structured review tool that turns six clinical and pathological factors from the index non-muscle invasive bladder cancer (NMIBC) into an individualised one- and five-year probability of recurrence and progression. It uses the Sylvester and colleagues 2006 EORTC risk tables, which the European Association of Urology still cites in its 2022 NMIBC guideline as the recommended way to estimate recurrence and progression risk before deciding on intravesical therapy and follow-up.

• • Treatment intensity discussion: A urologist uses it during a clinic visit to decide between a single instillation of chemotherapy, a full induction course of Bacillus Calmette-Guerin, or early radical cystectomy.
• • Follow-up interval planning: A multidisciplinary team uses it to set a cystoscopy and urine cytology interval that matches the patient's published risk band.
• • Patient communication: A nurse or trainee walks a newly diagnosed NMIBC patient through the six factors and the published risk band, anchoring the discussion in numbers rather than memory.

The EORTC risk tables were built from 2,596 patients across seven EORTC trials of stage Ta and T1 bladder cancer. The calculator keeps recurrence and progression separate, which matches the Sylvester 2006 design.

Use the result for documentation, clinic discussion, and shared decision-making. The probability bands should always be read alongside the cystoscopy schedule, urine cytology, upper-tract imaging, and any restaging TURBT the team has planned.

The EORTC bladder cancer calculator sits in the same urology clinic workflow as the Kidney Stone Calculator, so a patient staged for an index TURBT will often see both risk tools on the same visit when the team is also reviewing a stone history or hydronephrosis on imaging.

The calculator walks through the six EORTC factors in order, picks the highest-matching option in each, sums the recurrence and progression sub-scores separately, and looks each total up in the Sylvester 2006 EORTC risk table.

• Number of tumors: Single = 0, 2 to 7 = 3 (recurrence) or 3 (progression), 8 or more = 6 (recurrence) or 3 (progression).
• Tumor diameter: Less than 3 cm = 0; 3 cm or larger = 3 points in both sub-scores.
• Prior recurrence rate: Primary = 0; at most 1 per year = 2; more than 1 per year = 4 recurrence or 2 progression points.
• Stage: Ta = 0; T1 = 1 recurrence or 4 progression points.
• Concomitant CIS: No = 0; yes = 1 recurrence or 6 progression points.
• Grade (WHO 1973): G1 = 0; G2 = 1 recurrence and 0 progression; G3 = 2 recurrence and 5 progression points.

According to Sylvester et al. 2006, European Urology (EORTC risk tables), the EORTC risk tables for stage Ta T1 bladder cancer were derived from 2,596 patients across seven EORTC trials and translate six clinical and pathological factors into one- and five-year recurrence and progression probabilities

Reading serial clinical or pathological findings and translating them into a published risk band is the same workflow used in the PSA Doubling Time Calculator, where dated PSA readings are turned into a prostate cancer risk trend a urology team can act on.

Six clinical and pathological factors feed the EORTC recurrence and progression sub-scores, and each one is read at the index TURBT.

These six factors were the variables independently associated with recurrence or progression in the Sylvester 2006 combined analysis of 2,596 patients. The EAU 2022 NMIBC guideline uses the same six factors to assign each new NMIBC to a risk group.

The TIRADS Calculator turns a structured imaging report into a thyroid cancer risk band in the same way the six EORTC factors are read off the index TURBT pathology, which is why multidisciplinary teams that already work with cancer risk scoring systems adapt quickly to the EORTC layout.

Work through the six factors in any order, but record the sub-scores and the two totals so a second reviewer can challenge the inputs.

1. 1 Pull the index TURBT pathology report: Note the number of tumors, the diameter of the largest tumor, the T category, the WHO 1973 grade, and whether flat high-grade CIS is present.
2. 2 Count prior recurrences per year: Divide the total prior NMIBC recurrences by the years of follow-up since the first diagnosis to pick the matching band.
3. 3 Pick the highest-matching option in each factor: Use the dropdowns to select the matching option for each of the six factors. The recurrence and progression sub-scores update live.
4. 4 Read the recurrence and progression probabilities: The results panel shows the recurrence and progression totals, then the matching one-year and five-year probabilities from the Sylvester 2006 EORTC risk table bands. Record the band and the sub-scores in the chart note.
5. 5 Pair the result with the rest of the workup: Compare the calculator result with cystoscopy, urine cytology, upper-tract imaging, and any restaging TURBT the team has already planned.

A 67-year-old with a single 1.5 cm Ta G2 lesion and no CIS, with one recurrence in the past two years. Recurrence sub-score 3 (single 0, less than 3 cm 0, at-most-1-per-year 2, Ta 0, no CIS 0, G2 1); progression sub-score 2. Result: 24 percent recurrence and 1 percent progression at 1 year, and 46 percent recurrence and 6 percent progression at 5 years.

Cisplatin-based intravesical and systemic chemotherapy for bladder cancer is renally cleared, so the GFR Calculator is the usual companion to the EORTC result when the team is reviewing whether a patient can tolerate the planned regimen.

A clinician can sum the six EORTC factors by hand, but a calculator makes the tally consistent, traceable, and easy to defend.

• • Standardised review across providers: Urologists, oncology nurses, trainees, and pharmacists all work from the same six factors and the same Sylvester 2006 probability bands.
• • Separates recurrence and progression risk: The two sub-scores are summed independently, which mirrors the Sylvester 2006 design and avoids treating a moderate recurrence total as if it implied a moderate progression total.
• • Traceable sub-score record: Each of the six sub-scores is shown in the breakdown, so a later reviewer can challenge any single input without re-deriving the whole table.
• • Ties clinic to the EAU 2022 guideline: The six factors and the probability bands match the European Association of Urology 2022 NMIBC guideline.

Several things can move the recurrence and progression sub-scores up or down, and the EORTC risk tables carry a few well-known limitations.

• • The Sylvester 2006 cohort did not include patients treated with modern Bacillus Calmette-Guerin maintenance, so the published bands reflect the original trial treatment era.
• • The EORTC risk tables were built from patients enrolled in EORTC trials, who tend to be younger than the average population-level NMIBC patient; the calculator is a review aid, not a substitute for cystoscopy, urine cytology, upper-tract imaging, and multidisciplinary review.

According to Babjuk et al. 2022, European Urology (EAU NMIBC Guidelines), the EAU 2022 NMIBC guideline still recommends the EORTC scoring system as the preferred way to estimate the probability of recurrence and progression in Ta, T1, and CIS bladder cancer

When the EORTC band pushes the team toward Bacillus Calmette-Guerin induction or systemic chemotherapy, the ANC Calculator is the next tool in the clinic workflow to estimate febrile neutropenia risk from the planned regimen.